VIENNA (MedPage Today) -- Insulin glargine (Lantus) continued to carry no increased risk of cardiovascular events compared with standard care in an extension of the ORIGIN trial, researchers reported here. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment